Glutamyl- but not aspartyl-aminopeptidase activity is modified in serum of N-methyl nitrosourea-induced rat mammary tumours
BACKGROUND: The rat model of breast cancer induced by the administration of N-methyl-nitrosourea (NMU) constitutes a useful tool for dissecting the initiation, promotion and progression process of carcinogenesis. Angiogenesis, the recruitment of new blood vessels, is an essential component of the metastatic pathway. Tumour vessels have an aberrant response to constrictor hormones, such as angiotensin II (Ang II). Ang II degradation to form angiotensin III (Ang III) begins with the action of glutamyl aminopeptidase (GluAP) and aspartyl aminopeptidase (AspAP), named together as aminopeptidase A activity (APA). The present work analyses GluAP and AspAP activities in serum of NMU-induced rat mammary tumours, to evaluate the putative value of these activities as biological markers of the initiation and promotion of the disease.
MATERIALS AND METHODS: Serum AspAP and GluAP activities were measured fluorimetrically using their corresponding aminoacyl-beta-naphthylamide.
RESULTS: The increase found in GluAP but not in AspAP suggests an increase in Ang III and a decrease in Ang II serum circulating levels.
CONCLUSION: The decrease in Ang III may be responsible for the overexpression of AT1 receptors described in breast cancer. However, increased levels of Ang III, which exhibit the same affinity for the AT1 receptor, would favour the development of the disease.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2004 |
---|---|
Erschienen: |
2004 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Anticancer research - 24(2004), 2B vom: 08. März, Seite 801-5 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Carrera, María Pilar [VerfasserIn] |
---|
Themen: |
684-93-5 |
---|
Anmerkungen: |
Date Completed 19.07.2004 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM148504299 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM148504299 | ||
003 | DE-627 | ||
005 | 20231223045733.0 | ||
007 | tu | ||
008 | 231223s2004 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0495.xml |
035 | |a (DE-627)NLM148504299 | ||
035 | |a (NLM)15161030 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Carrera, María Pilar |e verfasserin |4 aut | |
245 | 1 | 0 | |a Glutamyl- but not aspartyl-aminopeptidase activity is modified in serum of N-methyl nitrosourea-induced rat mammary tumours |
264 | 1 | |c 2004 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 19.07.2004 | ||
500 | |a Date Revised 19.11.2015 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: The rat model of breast cancer induced by the administration of N-methyl-nitrosourea (NMU) constitutes a useful tool for dissecting the initiation, promotion and progression process of carcinogenesis. Angiogenesis, the recruitment of new blood vessels, is an essential component of the metastatic pathway. Tumour vessels have an aberrant response to constrictor hormones, such as angiotensin II (Ang II). Ang II degradation to form angiotensin III (Ang III) begins with the action of glutamyl aminopeptidase (GluAP) and aspartyl aminopeptidase (AspAP), named together as aminopeptidase A activity (APA). The present work analyses GluAP and AspAP activities in serum of NMU-induced rat mammary tumours, to evaluate the putative value of these activities as biological markers of the initiation and promotion of the disease | ||
520 | |a MATERIALS AND METHODS: Serum AspAP and GluAP activities were measured fluorimetrically using their corresponding aminoacyl-beta-naphthylamide | ||
520 | |a RESULTS: The increase found in GluAP but not in AspAP suggests an increase in Ang III and a decrease in Ang II serum circulating levels | ||
520 | |a CONCLUSION: The decrease in Ang III may be responsible for the overexpression of AT1 receptors described in breast cancer. However, increased levels of Ang III, which exhibit the same affinity for the AT1 receptor, would favour the development of the disease | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Biomarkers, Tumor |2 NLM | |
650 | 7 | |a Carcinogens |2 NLM | |
650 | 7 | |a Methylnitrosourea |2 NLM | |
650 | 7 | |a 684-93-5 |2 NLM | |
650 | 7 | |a Glutamyl Aminopeptidase |2 NLM | |
650 | 7 | |a EC 3.4.11.7 |2 NLM | |
700 | 1 | |a Ramírez-Expósito, María Jesus |e verfasserin |4 aut | |
700 | 1 | |a Valenzuela, María Teresa |e verfasserin |4 aut | |
700 | 1 | |a García, María Jesus |e verfasserin |4 aut | |
700 | 1 | |a Mayas, María Dolores |e verfasserin |4 aut | |
700 | 1 | |a Martínez-Martos, José Manuel |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 24(2004), 2B vom: 08. März, Seite 801-5 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2004 |g number:2B |g day:08 |g month:03 |g pages:801-5 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2004 |e 2B |b 08 |c 03 |h 801-5 |